ProQR Therapeutics N.V. Ordinary Shares (PRQR) Dividend History

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic eye diseases and other rare genetic disorders. Founded in 2012 and based in the Netherlands, it specializes in designing therapies that target the root causes of these conditions, aiming to provide transformative treatments for patients with limited options.

Website:

Dividend History

ProQR Therapeutics N.V. Ordinary Shares currently does not pay dividends

Company News

  • ProQR Announces First Quarter 2025 Operating and Financial Results

    ProQR Therapeutics reported its Q1 2025 financial results, highlighting progress in its Axiomer RNA editing pipeline, including the advancement of its lead program AX-0810 targeting NTCP for cholestatic diseases towards a CTA filing in Q2 2025. The company also strengthened its leadership team with new CFO and CMO appointments.

    GlobeNewswire Inc.
  • ProQR Announces Year End 2024 Operating and Financial Results

    ProQR Therapeutics is advancing its Axiomer™ ADAR-mediated RNA editing pipeline, with plans to file a CTA for its lead program AX-0810 targeting NTCP for Cholestatic diseases in Q2 2025. The company expects up to four clinical data readouts in 2025 and 2026, and has a strong financial position with €149.4 million in cash and cash equivalents as of the end of 2024.

    GlobeNewswire Inc.
    Featured Companies: LLY
  • ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

    ProQR Therapeutics, a company focused on RNA therapies, has appointed Dr. Peter Beal, a leading expert in ADAR and RNA biology, as its Chief ADAR Scientist. Dr. Beal will oversee the optimization and development of ProQR's Axiomer RNA editing platform.

    GlobeNewswire Inc.
  • ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

    ProQR Therapeutics, a company focused on RNA therapies, has announced the closing of a $63.0 million public offering and a $12.3 million private placement with Eli Lilly and Company.

    GlobeNewswire Inc.
    Featured Companies: LLY
  • ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

    ProQR Therapeutics announced the pricing of a $63.0 million public offering of 18 million ordinary shares at $3.50 per share. The company also entered into a concurrent private placement with existing shareholder Eli Lilly and Company to maintain its pro rata ownership.

    GlobeNewswire Inc.
    Featured Companies: LLY
Dividend data last updated 06/07/2025 07:52:33 UTC